Ambu A/S (AMBBY)
- Previous Close
19.75 - Open
19.00 - Bid --
- Ask --
- Day's Range
19.00 - 19.00 - 52 Week Range
9.45 - 19.75 - Volume
530 - Avg. Volume
285 - Market Cap (intraday)
5.06B - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
95.00 - EPS (TTM)
0.20 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 15, 2021
- 1y Target Est
--
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.
www.ambu.comRecent News: AMBBY
Performance Overview: AMBBY
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMBBY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMBBY
Valuation Measures
Market Cap
5.05B
Enterprise Value
5.09B
Trailing P/E
94.34
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.92
Price/Book (mrq)
6.19
Enterprise Value/Revenue
6.88
Enterprise Value/EBITDA
40.79
Financial Highlights
Profitability and Income Statement
Profit Margin
7.23%
Return on Assets (ttm)
4.54%
Return on Equity (ttm)
6.79%
Revenue (ttm)
5.07B
Net Income Avi to Common (ttm)
367M
Diluted EPS (ttm)
0.20
Balance Sheet and Cash Flow
Total Cash (mrq)
387M
Total Debt/Equity (mrq)
11.24%
Levered Free Cash Flow (ttm)
507.38M
Research Analysis: AMBBY
Company Insights: AMBBY
AMBBY does not have Company Insights